Biostar Pharmaceuticals (BSPM) Given Coverage Optimism Rating of 0.14
Media stories about Biostar Pharmaceuticals (NASDAQ:BSPM) have been trending somewhat positive on Saturday, according to Accern Sentiment. The research firm identifies negative and positive news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Biostar Pharmaceuticals earned a media sentiment score of 0.14 on Accern’s scale. Accern also gave media stories about the company an impact score of 46.6640847051924 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Biostar Pharmaceuticals (NASDAQ:BSPM) traded down $0.03 during mid-day trading on Friday, reaching $1.96. The company’s stock had a trading volume of 13,037 shares, compared to its average volume of 51,961. The firm has a market cap of $5.25, a price-to-earnings ratio of 2.84 and a beta of 1.87. Biostar Pharmaceuticals has a 52 week low of $1.18 and a 52 week high of $4.30.
Biostar Pharmaceuticals (NASDAQ:BSPM) last posted its quarterly earnings results on Wednesday, November 15th. The company reported ($0.50) earnings per share (EPS) for the quarter. During the same quarter in the prior year, the business earned ($3.12) earnings per share.
About Biostar Pharmaceuticals
Biostar Pharmaceuticals, Inc (Biostar) is a holding company. The Company, through its subsidiary, Shaanxi Biostar Biotech, Ltd. (Shaanxi Biostar), and its variable interest entities (VIEs), Shaanxi Aoxing Pharmaceutical Co, Ltd. (Aoxing Pharmaceutical) and Shaanxi Weinan Huaren Pharmaceuticals Ltd. (Shaanxi Weinan), develops, manufactures and markets pharmaceutical products for various diseases and conditions in the People’s Republic of China (PRC or China).
Receive News & Ratings for Biostar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biostar Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.